Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01013818 · ClinicalTrials.gov registry record · Phase 1
A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
A Phase 1 study, sponsored by Human Genome Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01013818 is a Phase 1 study that was terminated before completion, run by Human Genome Sciences. The registered enrollment target is 11 participants.
The verdict
NCT01013818, a Phase 1 study, was terminated before completion, sponsored by Human Genome Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients with relapsed or refractory lymphoid malignancies.
Interventions
- DRUG HGS1029
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01013818
The ClinicalTrials.gov registry entry for NCT01013818 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Human Genome Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HGS1029 is the first listed.
NCT01013818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01013818 about?
NCT01013818 is a clinical study titled "A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies". The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients with relapsed or refractory lymphoid malignancies.
What is the current status of trial NCT01013818?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2009-10. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01013818?
The interventions under investigation include: HGS1029 (DRUG).
Who is sponsoring clinical trial NCT01013818?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.